Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical trial NCT02446600 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02446600
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Tumor Ovarian Seromucinous Carcinoma Ovarian Serous Tumor Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Endometrioid Adenocarcinoma

Start date: 2016-03-28
Primary completion: 2020-02-23
Enrollment: 579

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.